Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1431FWO
- CEMIC, Otorhinolaryngology Department
-
Rio Cuarto, Argentina, X5800AEV
- Istituto Medico Rio Cuarto
-
-
-
-
-
Brno, Czech Republic, 61300
- University Hospital Brno - Children's Medical Centre
-
Hradec Kralove, Czech Republic, 500 05
- University Hospital Hradec Kralove
-
Olomouc, Czech Republic, 775 20
- University Hospital Olomouc
-
Plzen-Lochotin, Czech Republic, 30460
- University Hospital Pilsen- Paediatric Clinic
-
Praha, Czech Republic, 15006
- University Hospital Motol
-
Znojmo, Czech Republic, 669 02
- Hospital Znojmo, State-Funded Organisation, Department of Pediatrics
-
-
-
-
-
Budapest, Hungary, 1083
- Semmeleis University
-
Budapest, Hungary, 1097
- St Istvan and St Laszlo Corporate Hospital; Paediatric Intensive Care Unit
-
Budapest, Hungary, 1125
- The Municipal Council's St Janos Hospital and North Buda United Hospitals; Central Anaesthesiology and Intensive Care Unit
-
Dunaújváros, Hungary, 2400
- St Panthaleon Hospital; Central Department of Anaesthesiology and Intensive Care Unit
-
Gyula, Hungary, 5700
- Pandy Kalman County Hospital; Department of Central Anaesthesiology and Intensive Care Unit
-
-
-
-
-
Gdansk, Poland, 80-803
- Department of Pediatric Surgery and Urology of Medical University of Gdansk
-
Lodz, Poland, 91-738
- Department of Pediatric Anesthesiology and Intensive Care
-
Lublin, Poland, 20-093
- Department of Pediatric Anesthesiology and Intensive Care
-
Olsztyn, Poland, 10-561
- Department of Intensive Care and Anesthesiology
-
Wroclaw, Poland, 50-369
- Department of Pediatric Surgery
-
-
-
-
-
San Juan, Puerto Rico, PR 00936
- University Pediatric Hospital
-
-
-
-
-
Arkhangelsk, Russian Federation, 132002
- State Healthcare Institution Arkhangelsk Regional Children's Hospital
-
Saint Petersburg, Russian Federation, 190013
- Federal State Institution: St. Petersburg Research Institute of Ear, Throat, Nose and Speech under the MoH Care and Social Development of the Russian Federation
-
Saint Petersburg, Russian Federation, 191025
- International Clinic MEDEM
-
St-Petersburg, Russian Federation, 194100
- St. Petersburg State Pediatric Medical Academy
-
Yaroslavl, Russian Federation, 150042
- Yaroslavl Region State Healthcare Institution
-
-
-
-
-
Dnipropetrovsk, Ukraine, 49100
- Dnipropetrovsk Regional Childrens Clinical Hospital
-
Donetsk, Ukraine, 83052
- Regional Childrens Clinical Hospital
-
Ivano-Frankivsk, Ukraine, 76000
- Ivano-Frankivsk Regional Childrens Clinical Hospital
-
Kharkiv, Ukraine, 61000
- City Clinical Hospital n#30
-
Kyiv, Ukraine, 01133
- Research and Development Center for Prophylactic and Clinical Medicine
-
Kyiv, Ukraine, 01135
- National Specialized Childrens Hospital OKHMATDYT
-
Odesa, Ukraine, 65061
- V.P. Filatov Institute of Eye Diseases and Tissue Therapy
-
Zaporizhia, Ukraine, 69000
- Zaporizhia Regional Clinical Childrens Hospital
-
-
-
-
Alabama
-
Florence, Alabama, United States, 35630
- Shoals Clinical Research Associates
-
Sheffield, Alabama, United States, 35660
- Shoals Medical Research, LLC
-
-
District of Columbia
-
Washington DC, District of Columbia, United States, 20007
- Georgetown University Hospital
-
-
Florida
-
Miami, Florida, United States, 33136
- Bascom Palmer Eye Institute - University of Miami
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- Louisiana State University Health Sciences Center
-
-
Mississippi
-
Jackson, Mississippi, United States, 39202
- CRC of Jackson
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper University Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- The University of North Carolina Hospitals
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45255
- Clinical Trial Developers
-
-
Texas
-
Grapevine, Texas, United States, 76051
- Texas Orthopedic Specialist, P.A
-
Houston, Texas, United States, 77030
- Memorial Hermann Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patient aged from full term neonate to less than 17 years.
In-patient or out-patient scheduled to undergo one of the following procedures:
- ear, nose and throat surgery (e.g., tonsillectomy, adenoidectomy, myringotomy),
- eye surgery (e.g. strabismus, vitreoretinal, cataract surgery),
- urological surgery (e.g. orchidopexy, varicocoele),
- plastic reconstructive surgery (e.g. cleft lip/cleft palate, burn procedures involving the scalp),
- hernia repair,
- orthopedic surgery (e.g. foot and ankle deformities, arthroscopic surgeries, ACL surgery),.
- cardiac surgery,
- neurosurgery.
- Patient is scheduled to undergo surgery requiring general intravenous anesthesia
- Patient is scheduled to receive nitrous oxide during the maintenance phase of anesthesia
- Patient weighs at least 3.2 kg
- ASA physical status I, II or III
- Fertile patients (male or female) must use reliable contraceptive measures
- Female patients who have attained menarche must have a negative pregnancy test at the screening visit (Visit 1) and at study treatment visit (Visit 2)
- For patients with known hepatic impairment: in the Investigator's opinion, the impairment does not jeopardize the patient's safety during the study
- For patients with known renal impairment: in the Investigator's opinion, the impairment does not jeopardize the patient's safety during the study
Exclusion Criteria:
- Lactating females
- Patient aged ≤6 years who received any investigational drug within 90 days prior to Day 1, or patient aged >6 years who received any investigational drug within 30 days prior to Day 1 or is expected to receive investigational drugs prior to study completion.
- Patient having participated in any previous trial with palonosetron.
- History of allergy to any components or any other contraindications to the use of any 5-HT3 receptor antagonists
- Patient to undergo emergency surgery
- Patient scheduled to receive regional anesthesia (lumbar, epidural, spinal) alone or in conjunction with general intravenous anesthesia
- Patient scheduled to receive laryngeal mask anesthesia
- Patient scheduled to receive propofol during the maintenance phase of anesthesia
- Patient suffering from any concomitant disease uncontrolled by therapy, which, in the judgment of the Investigator, could compromise the outcome of surgery
- Patient with history of gastro-esophageal reflux (except for patients up to 12 months)
- Patient with ongoing vomiting from any organic cause
- Patient having experienced any vomiting, retching, or nausea within 24 hours prior to the administration of the study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Palonosetron and placebo to Ondansetron
Intervention: Drug: Palonosetron
|
Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
|
|
Active Comparator: Ondansetron and placebo to Palonosetron
Intervention: Drug: Comparator: Ondansetron
|
Single dose Ondansetron IV:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Patients With Complete Response
Time Frame: 0-24 hours after T0
|
Complete Response was defined as no vomiting, no retching, and no use of antiemetic rescue medication during the first 24 hours postoperatively, starting at T0.
Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.
|
0-24 hours after T0
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Patients With no Vomiting
Time Frame: 0-24 hours after T0
|
Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.
|
0-24 hours after T0
|
|
Proportion of Patients Without Emetic Episodes
Time Frame: 0-24 hours after T0
|
An emetic episode was defined as one or more continuous vomits (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents).
Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.
|
0-24 hours after T0
|
|
Proportion of Patients Without Antiemetic Rescue Medication
Time Frame: 0-24 hours after T0
|
Rescue medications are any medications with potential antiemetic effect taken in the 24 hours after patient wake-up from anaesthesia (T0).Time 0 (T0) was defined as the time when the patient wakes up and is able to show any active reaction postoperatively.
|
0-24 hours after T0
|
|
Proportion of Patients Without Nausea (Patient Aged > 6 Years)
Time Frame: 0-24 hours after T0
|
0-24 hours after T0
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Postoperative Nausea and Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Antipruritics
- Palonosetron
- Ondansetron
Other Study ID Numbers
Other Study ID Numbers
- PALO-10-14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.